Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Entecavir“
Suchtreffer
Begriffe & Kennungen
Baraclude · 4.5 · Entecavir is not a substrate, an inducer or an inhibitor of cytochrome P450 (CYP450) enzymes (see section 5.2)
Eintrag öffnenBaraclude · 4.5 · Entecavir is not a substrate, an inducer or an inhibitor of cytochrome P450 (CYP450) enzymes (see section 5.2)
Eintrag öffnenBaraclude · 4.5 · No pharmacokinetic interactions between entecavir and lamivudine, adefovir or tenofovir were observed.
Eintrag öffnenBaraclude · 4.5 · No pharmacokinetic interactions between entecavir and lamivudine, adefovir or tenofovir were observed.
Eintrag öffnenBaraclude · 4.5 · Since entecavir is predominantly eliminated by the kidney (see section 5.2), coadministration with medicinal p
Eintrag öffnenBaraclude · 4.5 · Since entecavir is predominantly eliminated by the kidney (see section 5.2), coadministration with medicinal p
Eintrag öffnenBaraclude · 4.8 · 8 In the clinical trials entecavir treatment was discontinued if patients achieved a prespecified response. If
Eintrag öffnenBaraclude · 4.8 · Adverse reactions considered at least possibly related to treatment with entecavir are listed by body system o
Eintrag öffnenBaraclude · 4.8 · Adverse reactions considered at least possibly related to treatment with entecavir are listed by body system o
Eintrag öffnenBaraclude · 4.8 · Experience in patients co-infected with HIV: the safety profile of entecavir in a limited number of HIV/HBV co
Eintrag öffnenBaraclude · 4.8 · Experience in patients co-infected with HIV: the safety profile of entecavir in a limited number of HIV/HBV co
Eintrag öffnenBaraclude · 4.8 · Experience in patients with decompensated liver disease: the safety profile of entecavir in patients with deco
Eintrag öffnenBaraclude · 4.8 · Experience in patients with decompensated liver disease: the safety profile of entecavir in patients with deco
Eintrag öffnenBaraclude · 4.8 · Gender/age: there was no apparent difference in the safety profile of entecavir with respect to gender ( 25%
Eintrag öffnenBaraclude · 4.8 · Gender/age: there was no apparent difference in the safety profile of entecavir with respect to gender ( 25%
Eintrag öffnenBaraclude · 4.8 · In the clinical trials entecavir treatment was discontinued if patients achieved a prespecified response. If t
Eintrag öffnenBaraclude · 4.8 · Laboratory test abnormalities: through week 48 among entecavir-treated patients with decompensated liver disea
Eintrag öffnenBaraclude · 4.8 · Laboratory test abnormalities: through week 48 among entecavir-treated patients with decompensated liver disea
Eintrag öffnenBaraclude · 4.8 · The safety of entecavir in paediatric patients from 2 to < 18 years of age is based on two clinical trials in
Eintrag öffnenBaraclude · 4.8 · The safety of entecavir in paediatric patients from 2 to < 18 years of age is based on two clinical trials in
Eintrag öffnen